JP Morgan Chase
TXMD icon

JP Morgan Chase’s TherapeuticsMD TXMD Stock Holding History

JP Morgan Chase’s Portfolio TXMD Stock Details TXMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-1,428
Closed -$259K – 5896
2019
Q3 		$259K Sell
1,428
-510
-26% -$71.9K ﹤0.01% 4510
2019
Q2 		$243K Buy
+1,938
New +$347K ﹤0.01% 4586
2019
Q1 		– Sell
-58
Closed -$11K – 6061
2018
Q4 		$11K Hold
58
– – ﹤0.01% 5427
2018
Q3 		$19K Buy
+58
New +$17.8K ﹤0.01% 5427

Other funds holding TXMD

RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
CC
Clearline Capital New York $1.93B AUM 38.13% 1-Year Est. Return
SCM
Squadron Capital Management Westmont, Illinois $273M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
TC
Tejara Capital London, United Kingdom $303M AUM 5.43% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $1.7B AUM 340.85% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

JP Morgan Chase's TXMD Position: Q1 2026 in Review

JP Morgan Chase held its TherapeuticsMD (TXMD) position steady in Q1 2026 at 293 shares worth $583. The position accounts for ﹤0.01% of the portfolio, ranked #7168.

JP Morgan Chase first reported a position in TXMD in Q2 2013 and has held it in 47 quarters since. The position peaked at $136M in Q3 2018. 49 funds tracked by Wall St. Rank hold TXMD as of Q1 2026.

  • JP Morgan Chase held 293 shares of TherapeuticsMD worth $583 as of Q1 2026.
  • JP Morgan Chase left its TherapeuticsMD share count unchanged in Q1 2026.
  • TherapeuticsMD made up ﹤0.01% of JP Morgan Chase's portfolio in Q1 2026, its #7168 holding.
  • JP Morgan Chase first reported a position in TherapeuticsMD in Q2 2013 and has held it in 47 quarters since.
  • JP Morgan Chase's TherapeuticsMD position peaked at $136M in Q3 2018.
  • 49 funds tracked by Wall St. Rank held TherapeuticsMD as of Q1 2026.

Based on JP Morgan Chase's 13F filing for Q1 2026, filed 13 May 2026.